5-HT1F receptor agonists in acute migraine treatment: A hypothesis

Cephalalgia

Volumn 23, Issue 8, 2003, Pages 776-785

  Ramadan, Nabih M ^a,b,c   Skljarevski, V ^a   Phebus, L A ^a   Johnson, K W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

5 HT1F; Clinical pharmacology; Clinical trials; Migraine; Pathophysiology; Serotonin

Indexed keywords

4991W93; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALNIDITAN; ANTIMIGRAINE AGENT; AVITRIPTAN; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE TARTRATE; FROVATRIPTAN; GLUTAMIC ACID; LY 302148; LY 306258; LY 397584; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; NARATRIPTAN; PLASMA PROTEIN; PROTEIN C FOS; RIZATRIPTAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ACUTE DISEASE; ASTHENIA; BRAIN BLOOD VESSEL; CLINICAL OBSERVATION; CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EXTRAVASATION; GENE EXPRESSION; GUINEA PIG; HUMAN; HYPOTHESIS; IC 50; IMMUNOREACTIVITY; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; PAIN; PARESTHESIA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE; SYMPTOM; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION; VASOCONSTRICTION; VASODILATATION; VERTIGO;

EID: 0141959078     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2003.00525.x     Document Type: Review

References (64)

1. Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates LH, Butina D. GR43175, a selective agonist for the 5-HT1-like receptor, in dog isolated saphenous vein. Br J Pharmacol 1988; 94:1123-32.
2. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16:157-68.
3. Goadsby P. Neuropeptides and migraine - a useful biological marker? Cephalalgia 1995; 15:384-90.
4. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99:202-6.
5. De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375:61-74.
6. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997; 8:2237-40.
7. Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol 1989; 163:133-6.
8. Humphrey PP, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 1990; 30:12-6.
9. Deliganis AV, Peroutka SK. 5-Hydroxtryptamine 1D receptor agonism predicts antimigraine efficacy. Headache 1991; 336:228-31.
10. Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci USA 1992; 89:3630-4.
11. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine - new insights. Can J Neurol Sci 1999; 26 (Suppl. 3):S12-9.
12. Adham N, Kao NT, Schecter LE, Bard J, Olsen M, Urquhart D et al. Cloning of another human serotonin receptor (5HT1F): a fifth 5HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993; 90:408-12.
13. Razzaque Z, Heald MA, Pickard JD, Maskell L, Beer MS, Hill RG, Longmore J. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol 1999; 47:75-82.
14. Cohen ML, Johnson KW, Schenck KW, Phebus LA. Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 1997; 17:631-8.
15. Bouchelet I, Cohen Z, Casae B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytriptamine receptors in human trigeminal ganglia and cerebral blood vessels. J Pharmacol Exp Ther 1996; 50:219-23.
16. Bouchelet I, Case B, Olivier A, Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 2000; 129:501-8.
17. Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994; 33:367-86.
18. Waeber C, Moskowitz MA. [3H] sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995; 352:263-75.
19. Pascual J, Del Arco C, Romon T, Del Olmo E, Pazos A. [3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors. Eur J Pharmacol 1996; 295:271-4.
20. Adham N, Bard JA, Zgombick JM, Durkin MM, Kucharewicz S, Weinshank RL et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology 1997; 36:569-76.
21. Cohen Z, Bouchelet I, Olivier A, Villemure JG, Ball R, Stanimirovic DB, Hamel E. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 1999; 19:908-17.
22. Ma QP. Co-localization of 5-HT (1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001; 12:1589-91.
23. Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998; 156:102-6.
24. 1F agonists, LY334370 and LY397584, inhibit both central and peripheral branches of trigeminal sensory afferents in rats. Cephalalgia 2000; 20:419 (Abstr.).
25. Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C. Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 1999; 369:271-7.
26. 1F receptor agonist LY334370. Cephalalgia 1999; 19:851-8.
27. 1F receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 1999; 290:935-9.
28. 2α. Br J Pharmacol 2000; 131:562-8.
29. Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation 1994; 90:1141-53.
30. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987; 7:4129-36.
31. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43 (Suppl. 3):S16-S20.
32. Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000; 20:43-51.
33. Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT (1B/1D) receptor agonist. Eur J Pharmacol 2000; 398:73-81.
34. Shepherd SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ. Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997; 36:525-33.
35. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165:251-8.
36. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988; 8:83-91.
37. Pappagallo M, Szabo Z, Esposito G, Lokesh A, Velez L. Imaging neurogenic inflammation in patients with migraine headache. Neurology 1999; 52 (Suppl. 2):A274-5 (Abstr.).
38. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183-7.
39. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15:384-90.
40. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 2000; 86:133-8.
41. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56.
42. Lassen LH, Jacobsen VB, Pedersen PA, Sperling B, Iversen HK, Olesen J. hCGRP-induced headache in migraineurs. Cephalalgia 1999; 19:316 (Abstr.).
43. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67:375-8.
44. Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000; 47:238-41.
45. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17:785-90.
46. Ramadan NM. Acute treatments: some blind alleys. Curr Med Res Op 2001; 17:s71-80.
47. May A, Shepheard SL, Knorr M, Effert R, Wessing A, Hargreaves RJ et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998; 121:1231-7.
48. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997; 61:2117-26.
49. 35S]GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 1998; 352:117-24.
50. Dupuis DS, Colpaert FC, Pauwels PJ. G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br J Pharmacol 1998; 124:283-90.
51. Boers PM, Donaldson C, Zagami AS, Lambert GA. 5-HT(1A) and 5-HT(1B/1D) receptors are involved in the modulation of the trigeminovascular system of the cat: a microiontophoretic study. Neuropharmacology 2000; 39:1833-47.
52. 1F receptor agonist. Cephalalgia 1997; 17:398-9. (Abstr.)
53. 1F receptor. Soc Neurosci 1996; 22:1331 (Abstr.).
54. Pereira A, Granier LA, Vandenhende F, de Suray JM, Onkelinx C. Safety and pharmacokinetics of high doses of LY334370, a selective serotonin IF receptor agonist (SSOFRA), during and outside an acute migraine attack. Cephalalgia 1999; 19:368 (Abstr.).
55. Granier LA, Gossen D, Vandenhende F. Safety, pharmacokinetics, and efficacy of intravenous LY334370. Cephalalgia 2000; 20:351-2 (Abstr.).
56. Granier LA, Vandenhende F, Gossen D, Ramadan NM. Safety and efficacy of LY334370 IV during an acute migraine. Neurology 2000; 54:A15 (Abstr.).
57. Gossen D, Granier LA, Vandenhende F. Oral LY334370 in migraine. Results of Phase 1 studies. Cephalalgia 2000; 20:349 (Abstr.).
58. 1F receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 2001; 358:1230-4.
59. Hamel E. Serotonin receptors. Relevance to migraine pathogenesis and treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000:133-9.
60. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121:157-64.
61. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5-HT (1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 2001; 133:1029-34.
62. Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 1999; 22:123-36.
63. 1B/1D receptor: a central action in migraine? Ann Neurol 1998; 43:711-8.
64. Maassen VanDenBrink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauwerse HG, Saxena PR et al. Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 1998; 77:415-20.